A Phase III, Multicenter, Randomized Controlled Trial Investigating 1-cm Versus 2-cm Surgical Excision Margins for Stage II Primary Cutaneous Melanoma (MelMarT-II)
Ann Surg Oncol. 2022 Apr 22.
doi: 10.1245/s10434-022-11766-z.
Online ahead of print.
1 Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3740, Bethesda, MD, 20892, USA.
2 John Wayne Cancer Institute, Santa Monica, CA, USA.
3 Department of Plastic & Reconstructive Surgery, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK.
4 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
5 Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3740, Bethesda, MD, 20892, USA. jonathan.hernandez@nih.gov.
6 Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA. mlowe3@emory.edu.